• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nkarta, Inc. - Common Stock (NQ:NKTX)

    2.390 +0.100 (+4.37%)
    Streaming Delayed Price Updated: 2:10 PM EDT, Aug 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 274,693
    Open 2.350
    Bid (Size) 2.380 (500)
    Ask (Size) 2.390 (400)
    Prev. Close 2.290
    Today's Range 2.320 - 2.405
    52wk Range 1.700 - 3.720
    Shares Outstanding 48,934,928
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
    From Cyllene Therapeutics
    Via GlobeNewswire
    News headline image
    Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
    From Nkarta, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +27.8%
    +27.8%
    1 Month
    -29.3%
    -29.3%
    3 Month
    -24.1%
    -24.1%
    6 Month
    +24.5%
    +24.5%
    1 Year
    +14.4%
    +14.4%

    More News

    Read More
    News headline image
    After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
    From Biotech Insider
    Via GlobeNewswire
    Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances ↗
    Via Chartmill
    News headline image
    Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta to Participate in Needham Virtual Healthcare Conference
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta to Participate in March Investor Conferences
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta to Participate in Evercore Healthcare Conference
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta to Participate in November Investor Conferences
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Nkarta Posts Narrower Loss in Q2 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space ↗
    Via Benzinga
    News headline image
    This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
    Via Benzinga
    News headline image
    Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
    From Nkarta, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Thursday's session ↗
    Via Chartmill
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? ↗
    Via Benzinga

    Frequently Asked Questions

    Is Nkarta, Inc. - Common Stock publicly traded?
    Yes, Nkarta, Inc. - Common Stock is publicly traded.
    What exchange does Nkarta, Inc. - Common Stock trade on?
    Nkarta, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nkarta, Inc. - Common Stock?
    The ticker symbol for Nkarta, Inc. - Common Stock is NKTX on the Nasdaq Stock Market
    What is the current price of Nkarta, Inc. - Common Stock?
    The current price of Nkarta, Inc. - Common Stock is 2.390
    When was Nkarta, Inc. - Common Stock last traded?
    The last trade of Nkarta, Inc. - Common Stock was at 08/07/26 02:10 PM ET
    What is the market capitalization of Nkarta, Inc. - Common Stock?
    The market capitalization of Nkarta, Inc. - Common Stock is 116.95M
    How many shares of Nkarta, Inc. - Common Stock are outstanding?
    Nkarta, Inc. - Common Stock has 117M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.